NOVAVAX INC
NT 10-K, 1999-04-01
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: AMERIPRIME FUNDS, 497, 1999-04-01
Next: MEDPARTNERS INC, NT 10-K, 1999-04-01



<PAGE>   1
                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, DC 20549

                                 FORM 12b-25


                         NOTIFICATION OF LATE FILING

(CHECK ONE): [X] Form 10-K  [ ] Form 20-F  [ ] Form 11-K  [ ] Form 10-Q
             [ ] Form N-SAR

             For Period Ended:    12/31/98
                               ------------------       
             [ ] Transition Report on Form 10-K 
             [ ] Transition Report on Form 20-F 
             [ ] Transition Report on Form 11-K 
             [ ] Transition Report on Form 10-Q 
             [ ] Transition Report on Form N-SAR
             For the Transition Period Ended: 
                                              ---------------------


     NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION
                HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above identify 
the Item(s) to which the notification relates: 

- -------------------------------------------------------------------------------

PART I - REGISTRANT INFORMATION

Novavax, Inc.
- -------------------------------------------------------------------------------
Full name of registrant


- -------------------------------------------------------------------------------
Former name, if applicable:


8320 Guilford Road
- -------------------------------------------------------------------------------
Address of principal executive office (Street and number):


Columbia, Maryland 21046
- -------------------------------------------------------------------------------
City, State and Zip Code

PART II.  RULE 12b-25 (b) AND (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check appropriate box.)

[X]  (a)   The reasons described in reasonable detail in Part III of this form
           could not be eliminated without unreasonable effort or expense;

[X]  (b)   The subject annual report, semi-annual report, transition report on
           Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be 
           filed on or before the 15th calendar day following the prescribed 
           due date; or the subject quarterly report or transition report on 
           Form 10-Q, or 
                            
<PAGE>   2
           portion thereof will be filed on or before the fifth calendar day 
           following the prescribed due date; and

[ ]  (c)   The accountant's statement or other exhibit required by Rule 
           12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q,
N-SAR or the transition report portion thereof could not be filed within the
prescribed time period. (Attach extra sheets if needed.) The Company is unable 
to file its Annual Report on Form 10-K for the year ended December 31, 1998 by 
March 31, 1999 because the audit of its financial statements has been 
unavoidably delayed due in part to the departure of the Company's former 
chief financial officer.

PART IV - OTHER INFORMATION

(1)      Name and telephone number of person to contact in regard to this
         notification:

           Donald J. MacPhee          301                  854-3900 Ext. 226
         -----------------------------------------------------------------------
               (Name)              (Area code)             (Telephone number)


(2)      Have all other periodic reports required under Section 13 or 15(d) of
         the Securities Exchange Act of 1934 or Section 30 of the Investment
         Company Act of 1940 during preceding 12 months or for such shorter
         period that the registrant was required to file such report been filed?
         If the answer is no, identify report(s).
                  [X] Yes [ ] No

         -----------------------------------------------------------------------

(3)      Is it anticipated that any significant change in results of operations
         from the corresponding period for the last fiscal year will be
         reflected by the earnings statements to be included in the subject
         report or portion thereof? 
                  [X] Yes [ ] No


         If so: attach an explanation of the anticipated change, both
         narratively and quantitatively, and, if appropriate, state the reasons
         why a reasonable estimate of the results cannot be made.

         The Company anticipates that its financial statements for the year 
         ended December 31, 1998 will show an increase in net loss and net loss 
         applicable to common stockholders of approximately $250,000 and  
         $1,000,000, respectively, over the net loss and net loss applicable to
         common stockholders of $4,546,000 reported for the year ended December 
         31, 1997.
         =======================================================================

                               NOVAVAX, INC.
              ------------------------------------------------
                (Name of registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.


Date: March 31, 1999      By:     /s/ DONALD J. MACPHEE
                              --------------------------------------------------
                                  Donald J. MacPhee, Chief Financial Officer
                          

INSTRUCTION.  The form may be signed by an executive officer of the registrant
or by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission